To assess the effects of the drug on improving disease phenotype, we examined the expression of the epithelial markers filaggrin, loricrin and elafin in the epidermis of cytokine-induced psoriasis models and AD models before and after tofacitinib treatment by immunohistology (Fig. 8). This evidence concerns the gene LORICRIN and psoriasis.